Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices (Popeye)

21 marzo 2016 aggiornato da: Professor Lars Ove Dragsted, University of Copenhagen

Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices - a Explorative Study in Short-bowel Patients and Healthy Controls - The "Popeye-study"

Absorption and metabolism of carotenoids from two types of spinach preparations will be investigated in two study groups, short bowel/ileostomy and healthy, respectively.

The study will be conducted as a randomised, controlled, 2-way crossover study in 24 participants (12 in each group), randomized to two sequences (1-2, 2-1) of interventions with a more and a less bio-accessible spinach preparation. The serum, chylomicron and fecal/effluent levels of lutein and beta-carotene will be determined.

Panoramica dello studio

Descrizione dettagliata

Absorption and metabolism of carotenoids from two types of spinach preparations will be investigated in two study groups, short bowel/ileostomy and healthy, respectively.

The study will be conducted as a randomised, controlled, 2-way crossover study. Twenty four participants (12 in each group) will be randomized to two sequences (1-2, 2-1) of interventions with a more and a less bio-accessible spinach preparation (differentiates only on the basis of particle size).

The intervention period is sub-divided into three parts: run-in period (48 hours) with a standardized low-carotenoid diet, 0-24 hours (follow-up period 1 (FP1)) and 24 hours - 2 weeks (FP2). The intervention periods will be separated by a wash-out period of at least 14 days.

At start of each intervention, the intervention meal (breakfast) is served, followed by standardized, carotenoid-free meals in the following 24 hours. Participants will in FP1 and FP2 receive an intervention meal every second day. Participants will otherwise keep their habitual diets during these follow-up periods.

Study participants are asked to collect urine during 24 hours before and after the first intervention meal in each period. They will also collect feces/ileostomy efflux for 24 hours before and after initiation of the intervention for short bowel/ileostomy patients and for 48 periods in the healthy volunteers, respectively. Overnight-fasting serum samples are drawn at day 1, 7 and 15 of each intervention period. On day 1 plasma samples are drawn at 0,1, 3, 4, 6, 7, 9 and 24 hours post first intervention meal.

Plasma and effluent levels of lutein and beta-carotene will be determined and chylomicrons are also separated from these samples for determination of carotenoids.

Volunteers also have their macula examined for density of the yellow spot before and after the intervention. Plasma and effluent levels of other carotenoids as well as fat-soluble vitamins are also determined. The samples will also be subjected to metabolic profiling for further exploration and hypothesis generation.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

22

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Copenhagen Ø, Danimarca, 2100
        • Rigshospitalet, Department of Gastroenterology, CA-2121
      • Frederiksberg C, Danimarca, 1958
        • Department of Nutrition, Exercise and sports, University of Copenhagen

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

List of inclusion criteria:

  • Healthy adults (18-80 years old)
  • Body Mass Index (BMI) between 18,9-28
  • Normal fasting blood glucose (BS) (1,9-5,6 mmol/L)
  • Tolerates: Potatoes, rice, chicken, meat (non vegan/vegetarian).

List of exclusion criteria:

  • Intestinal diseases (among healthy controls), systemic infections, psychiatric disorders, metabolic diseases (incl. diabetes), and any clinical condition/circumstance which assessed by the study official makes the person unfit for participation in the trial.
  • Patients diagnosed with short bowel syndrome (SBS).
  • Chronic or frequent use of medication. Primarily consumption of drugs with known effect/side effects on fat absorption. Further, anticoagulants (Marevan) and systemic treatment with glucocorticoids.
  • Have or have had a drug addiction
  • Smokers
  • Alcohol consumption beyond the recommended (7/14 units per week for women/men, respectively)
  • Intake of vitamins or other supplements (3 months before the study and during the study) (healthy controls). Subjects from the patient group included only with stable intake of dietary supplements through the last 3 months.
  • Sampling or donation of larger amount of blood e.g. as blood donors or to other scientific experiments from 3 months before the study until its completion.
  • allergy or intolerance to any of the foods included in the study.
  • Women who are nursing, pregnant or planning pregnancy
  • Not able to comply with the procedures protocol.
  • Macular degeneration to a degree greeter than or equal to a surface area with one or more drusen larger than 125 microns in diameter in at least one eye.
  • Cataracts, macular- or other ocular disease, preventing depiction of xanthophyll pigment.

The following separate registered information was additionally recorded for short bowel/ileostomy patients:

  • Time since operation (stable, >1 year post operation)
  • Type of disease/background for operation
  • Intestinal anatomy (inclusive length and type of residual intestine)
  • Type and doses of vitamin and other types of supplementation

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Spinach - Whole leaf (10 mg lutein)

1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.

Followed by:

Minced spinach (10 mg lutein) given every second day for a 15 days period.

Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Sperimentale: Spinach - Minced (10 mg lutein)

2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.

Followed by:

Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.

Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Serum concentration of lutein and beta-carotene
Lasso di tempo: 15 days
Difference in serum concentration of lutein and beta-carotene between baseline and the end of each intervention period.
15 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Concentration of lutein and beta-carotene in the chylomicron/TLR fraction
Lasso di tempo: 24 hours
Changes in concentration of lutein and beta-carotene in the chylomicron/TLR fraction (area under the curve, AUC) 24 hours post first intervention meal in each intervention periods.
24 hours
Total lutein and beta-carotene sekretion with feces/ileostomy-efflux
Lasso di tempo: 48/24 hours
Total lutein and beta-carotene sekretion with feces/ileostomy-efflux 48 and 24 hours postprandial, for healthy and ileostomy patients, respectively.
48/24 hours
Concentration of other carotenoids in the chylomicron/TLR fraction
Lasso di tempo: 24 hours
Changes in concentration of other carotenoids in the chylomicron/TLR fraction (area under the curve, AUC) 24 hours post first intervention meal in each intervention periods.
24 hours
Serum concentration of other carotenoids
Lasso di tempo: 15 days
Difference in serum concentration of other carotenoids between baseline and the end of each intervention period.
15 days
Serum concentration of other fat-soluble vitamins
Lasso di tempo: 15 days
Difference in serum concentration of other vitamins (A, E; D, K) between baseline and the end of each intervention period.
15 days
Changes in metabolic markers
Lasso di tempo: 24 hours
Changes in overall metabolic markers from urine 24 hours postprandial
24 hours
Changes in metabolic markers
Lasso di tempo: 24 hours
Changes in overall metabolic markers in the chylomicron/TLR fraction 24 hours postprandial
24 hours
Changes in metabolic markers
Lasso di tempo: 15 days
Changes in overall metabolic markers in serum at the end of each intervention period.
15 days
Level of optical density of the macula lutea
Lasso di tempo: Baseline
Level of optical density in the macula lutea (MPOD), in the spectra where xanthophyll pigment is absorbing light.
Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 gennaio 2015

Completamento primario (Effettivo)

1 dicembre 2015

Completamento dello studio (Effettivo)

1 dicembre 2015

Date di iscrizione allo studio

Primo inviato

17 maggio 2015

Primo inviato che soddisfa i criteri di controllo qualità

18 maggio 2015

Primo Inserito (Stima)

21 maggio 2015

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

22 marzo 2016

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 marzo 2016

Ultimo verificato

1 marzo 2016

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • M220
  • H-3-2014-112/46407 (Altro identificatore: The Danish Ethics Committee)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi